Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wai Yuen Tong Medicine HoldingsHKSE:00897 38 EBITDA Margin % is 2.73% as of Mar. 2026, which is 83% below its 10-year median of 15.95. GuruFocus rates HKSE:00897 with a GF Score™ of 38/100 and a GF Value™ of HK$0.29 (Fairly Valued). The stock has 2 warning signs investors should review. Among 957 Drug Manufacturers companies, Wai Yuen Tong Medicine Holdings ranks worse than 71.26% on this metric.
Wai Yuen Tong Medicine Holdings (HKSE:00897) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Wai Yuen Tong Medicine Holdings EBITDA Margin % Related Terms
Wai Yuen Tong Medicine Holdings EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wai Yuen Tong Medicine Holdings EBITDA Margin % Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Wai Yuen Tong Medicine Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wai Yuen Tong Medicine Holdings EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Wai Yuen Tong Medicine Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Wai Yuen Tong Medicine Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wai Yuen Tong Medicine Holdings (HKSE:00897) has a EBITDA Margin % of 2.73% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Wai Yuen Tong Medicine Holdings and its competitors. This is 83% below median its historical median of 15.95. According to the industry distribution chart, Wai Yuen Tong Medicine Holdings ranks #682 out of 957 companies in the Drug Manufacturers industry, placing it in the top 71.3%.
Is Wai Yuen Tong Medicine Holdings' EBITDA Margin % too high?
Wai Yuen Tong Medicine Holdings' current EBITDA Margin % of 2.73% is 83% below median its 10-year median of 15.95. The Drug Manufacturers industry median EBITDA Margin % is 12.61. Wai Yuen Tong Medicine Holdings' value of 2.73% is 78.4% below this industry median. Based on the distribution chart, Wai Yuen Tong Medicine Holdings ranks #682 out of 957 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Wai Yuen Tong Medicine Holdings has a GF Score™ of 38/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Wai Yuen Tong Medicine Holdings' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Wai Yuen Tong Medicine Holdings ranks #682 out of 957 companies for EBITDA Margin %. This places Wai Yuen Tong Medicine Holdings in the lower half of its industry. The industry median EBITDA Margin % is 12.61. Wai Yuen Tong Medicine Holdings' value of 2.73% is 78.4% below this benchmark. While the company's 10-year median is 15.95 vs. the industry median of 12.61, Wai Yuen Tong Medicine Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.61, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wai Yuen Tong Medicine Holdings's current EBITDA Margin % of 2.73% is 78.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Wai Yuen Tong Medicine Holdings and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wai Yuen Tong Medicine Holdings's current EBITDA Margin % is 2.73%, which is 83% below median its own 10-year median of 15.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wai Yuen Tong Medicine Holdings stock overvalued right now?
Based on GuruFocus' analysis, Wai Yuen Tong Medicine Holdings (HKSE:00897) is currently considered Fairly Valued. The stock's GF Value™ is HK$0.29, compared to a current price of HK$0.29 — trading right at its estimated fair value. The current EBITDA Margin % is 2.73%, which is 83% below median its 10-year median of 15.95 and 78.4% below the Drug Manufacturers industry median of 12.61. Wai Yuen Tong Medicine Holdings' overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Wai Yuen Tong Medicine Holdings (HKSE:00897), the current EBITDA Margin % is 2.73% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wai Yuen Tong Medicine Holdings (HKSE:00897) Overvalued in 2026?
Based on GuruFocus' analysis, Wai Yuen Tong Medicine Holdings stock appears to be undervalued.
The current stock price of HK$0.29 is trading 0% below its estimated GF Value™ of HK$0.29.
GuruFocus considers Wai Yuen Tong Medicine Holdings to be Fairly Valued.
Key valuation signals for HKSE:00897:
EBITDA Margin %: 2.73% (83% below median its 10-year median of 15.95)
GF Value™: HK$0.29 vs. price of HK$0.29 (0% below fair value)
Industry Position: 78.4% below the Drug Manufacturers median (#682 of 957)
No single metric tells the full story. See the HKSE:00897 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wai Yuen Tong Medicine Holdings Ltd is an investment holding company. The company's operating segment includes production and sale of Chinese pharmaceutical and health food products; production and sale of Western pharmaceutical and health food products and property investment and management and sale of properties. It generates maximum revenue from the production and sale of Chinese pharmaceutical and health food products which include manufacturing, processing, and sale of traditional Chinese medicine which includes Chinese medicinal products sold under the brand name Wai Yuen Tong. Geographically, it derives a majority of revenue from Mainland China.
38GF Score
Get the complete analysis for HKSE:00897
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00897 has been successfully added to your 
